These results demonstrated that the risk model constructed with HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH could not accurately predict survival in ATRX-mt glioma patients, although it could in ATRX-wt glioma patients. This evidence concerns the gene ATRX and central nervous system cancer.